Genmab A/S Stock 12‑Month Price Target Raised to $42, Implies 9% Upside

Genmab and AbbVie's Epkinly, combined with chemotherapy, reduced disease progression or death risk by 51% in a Phase 3 lymphoma trial. The results exceeded expectations and could boost Epkinly's sales. Genmab reported $312M in Epkinly sales in H1 2024, and its shares rose 14% on the news. Epkinly may become the first drug of its kind approved for first-line DLBCL.

Genmab A/S and AbbVie reported a 51% reduction in progression or death risk in a Phase 3 trial of epcoritamab plus R-CHOP for high-risk lymphoma patients. The study met its primary endpoint with a hazard ratio of 0.49. Genmab's shares rose 10.73% on the news. The companies plan to consult regulators and present data at a medical meeting.

Genmab and AbbVie reported that their drug epcoritamab, when combined with standard treatment, reduced the risk of cancer progression or death by 51% in a Phase 3 trial for diffuse large B-cell lymphoma. The companies plan to discuss the findings with regulators. Genmab's shares rose 9%, while AbbVie's futures remained flat.

AbbVie (ABBV) and Genmab (GMAB) reported positive Phase III trial results for epcoritamab in DLBCL patients. The treatment, combined with standard care, showed promise in newly diagnosed cases with IPI scores of 2 to 5.

AbbVie and Genmab reported positive Phase III trial results for epcoritamab combined with R-CHOP in DLBCL patients. The combination showed a 51% reduction in progression or death risk versus R-CHOP alone. The companies plan to share full data and consult regulators. Epcoritamab is jointly developed and not yet approved for this use.

European shares rose, with the STOXX 600 up 0.8% to 638.41, led by Genmab's 7.6% gain after positive drug trial results. Healthcare sector gained 1.6%. Euro zone bond yields eased after recent highs. Upcoming data includes euro zone retail sales and UK PMI. Euro near 17-month low due to political uncertainty.